## INFORMATION DISCLOSURE STATEMENT

Address to: Assistant Commissioner for Patents Washington, D.C. 20231

Attorney Docket	AERX058CON3
First Named Inventor	Gonda et al.
Application Number	To Be Assigned
Filing Date	Herewith U
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Title	A METHOD OF TREATING DIABETES
	MELLITUS IN A PATIENT

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application Serial No. 09/686,212 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: \_\_\_\_\_5/3/01

By: \_\_\_\_\_

Registration No. 39,740

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, California 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\AERX (Aradigm)\058con3\ids.doc